As part of the collaboration, Avalon’s expertise and bio-manufacturing infrastructure and clinical study implementation resources will be leveraged along with BOKU professors scientific capabilities and laboratory expertise.
BOKU professors have already created the approaches required to synthesise conjugate vaccines with an S-layer artificial viral envelope linked to a viral antigen. Do you see impact on recruitment in your company due to COVID-19 pandemic?View ResultsAs proof of concept, the researchers demonstrated that these types of protein conjugate vaccine candidates could induce immune-protective antibody responses.